1. Home
  2. STTK

STTK

Shattuck Labs Inc.

Logo Shattuck Labs Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 3:32pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Founded: 2016 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 442.0M IPO Year: 2020
Target Price: $20.00 AVG Volume (30 days): 318.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.05 EPS Growth: N/A
52 Week Low/High: $1.33 - $11.11 Next Earning Date: 05-07-2024
Revenue: $1,657,000 Revenue Growth: 154.14%
Revenue Growth (this year): -37.6% Revenue Growth (next year): N/A

Share on Social Networks: